CHRISTINA JONES: Open Payments
NPI 1184754723 · SULPHUR, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$40,698 in 117 payments from 11 companies in 2025. Trend: 2023 $701 · 2024 $739 · 2025 $40,698
Speaker / faculty: $29,165Travel & lodging: $8,867Food & beverage: $2,665
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 28 | $23,711 |
| Indivior Inc. | 40 | $16,124 |
| ABBVIE INC. | 15 | $258 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $182 |
| Teva Pharmaceuticals USA, Inc. | 14 | $156 |
| Neurocrine BioSciences, Inc. | 5 | $118 |
| Braeburn Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 2 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: Epclusa, SUBLOCADE, VRAYLAR, CAPLYTA, INGREZZA, AUSTEDO XR, UZEDY, BRIXADI.
Industry payments across LA — which companies pay providers there.
